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Hyperthyroidism
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Abstract
Excess level of thyroid hormones in blood is thyrotoxicosis, which is respon-
sible for clinical syndrome of hypermetabolism, sympathetic hyperactivity. 
Hyperthyroidism is the term used to denote the overproduction of thyroid 
hormones from the thyroid gland. Hyperthyroidism is possible with hyperactive 
thyroid gland due to multi/solitary nodular thyroid disease or Grave’s disease. 
Thyrotoxicosis associated with thyroiditis is not hyperthyroidism. Treatment of 
hyperthyroidism is with anti-thyroid drugs (ATT), radio-active iodine ablation 
(RAI), or thyroid surgery; whereas, treatment of thyroiditis is symptomatic.
Keywords: thyrotoxicosis, hyperthyroidism, thyroiditis, anti-thyroid drugs (ATT), 
radio-active iodine ablation (RAI)
1. Introduction
Thyroid gland is a butterfly shaped gland located in front of neck. Thyroid gland 
synthesises and secretes thyroxine under influence of thyroid stimulating hormone 
(TSH). Hyperproduction and secretion of thyroxine is called as hyperthyroidism 
and presence of excess amount of thyroxine in blood is called as thyrotoxicosis. 
Hence presence of thyrotoxicosis does not necessarily means presence of hyperthy-
roidism, as thyrotoxicosis can be due to other reasons like thyroiditis, overdose of 
thyroxine tablets, ectopic sources like strauma ovarii producing excess thyroxine, 
etc. An approach to diagnose thyrotoxicosis is shown in Figure 1.
Figure 1. 
Approach to thyrotoxicosis.
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Treatment of thyrotoxicosis is symptomatic and the treatment of the cause, 
but treatment of hyperthyroidism is divided in three parts. First antithyroid drugs 
(ATD), radioactive iodine and thyroid surgery. The prevalence of hyperthyroidism 
is 1.2–1.6, 0.5–0.6 overt and 0.7–1.0% subclinical [1, 2]. The most frequent causes 
are Graves’ disease (GD) and toxic nodular goitre.
1.1 Prevalence
Prevalence of thyroid disease varies with iodine sufficiency of the region The 
National health and nutrition examination survey (NHANES III)[3] and epidemic 
survey in UK [4] demonstrates female preponderance of thyroid diseases and lower 
incidence of hyperthyroidism with 1–2% prevalence in women and 1/10th in men.
2. Clinical manifestations
Hyperthyroidism can mimic other health problems, which can make it difficult to 
diagnose. It can also cause a wide variety of signs and symptoms like, Unintentional 
weight loss, palpitations, missed heartbeats, increased appetite, nervousness, 
anxiety and irritability, tremulousness, excess sweating, menstrual irregularity, heat 
intolerance, changes in bowel patterns especially more frequent bowel movements, 
goitre, easy fatigue, muscular weakness, insomnia, thinning of skin, hair loss. 
Elderly are either asymptomatic or may have palpitations, easy fatigue, etc.
Signs include tremors, warm handshake, fast tachycardia/arrhythmia, flushing 
over upper body, brisk reflexes, goitre and prominent eyes. Early diagnosis has 
become possible because of easy availability of blood investigations for thyroid.
Cause of patient’s thyrotoxicosis can be guessed from presentation of patient and 
disease duration. Patients with hyperthyroidism have symptoms since months and 
dating back is usually difficult, patients of acute thyrotoxicosis due to thyroiditis 
usually date back their signs and symptoms. Many patients having mild thyrotoxi-
cosis attribute their symptoms to day to day fatigue, stress, etc.
Easy access to blood tests of thyroid has made diagnosis of thyrotoxicosis easy. 
It is important to differentiate between thyrotoxicosis and hyperthyroidism before 
anti thyroid drugs are initiated.
Clinical manifestations involve multiple systems of the body as follows.
2.1 Cardiovascular system
Alterations in cardiovascular function are due to increased circulatory demand 
that result from the hyper metabolism, first, in heart rate, and with more severe dis-
ease, in stroke volume [5]. Widening of the pulse pressure results from the increase in 
systolic and decrease in diastolic pressure due to reduced peripheral resistance [6, 7].
2.2 Protein, carbohydrate, and lipid metabolism
Both synthesis and degradation rates of proteins are increased indicated by 
muscle wasting. Uncontrolled diabetes can be due to increased degradation rate of 
insulin. Lipolysis is predominantly observed [8].
2.3 Sympathetic nervous system and catecholamines
The improvement in cardiac function with β-blockade in patients with 
hyperthyroidism has led to the concept that there is increased sympathetic 
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tone or increased cardiac sensitivity to the sympathetic nervous system in 
these patients [9].
2.4 Nervous system
Nervousness, emotional lability, and hyperkinesia are major symptoms.
Emotional lability mental disturbance may be severe; the patient shifts positions 
frequently, and movements are quick, jerky, exaggerated, and often purposeless.
In children, inability to focus may lead to deterioration of school performance. 
A fine tremor of the hands, tongue, or lightly closed eyelids is observed on clinical 
examination.
2.5 Muscle
Generalised wasting associated with weight loss. The weakness is most prominent 
in the proximal muscles of the limbs, myopathy is also a feature of disease which 
involves distal muscles, ocular myopathy may mimic myasthenia gravis. Periodic 
paralysis of the hypokalemic type may occur together with thyrotoxicosis [10–12].
2.6 Eyes
As shown in Figure 2, proptosis, stare, lid lag, globe lag, dry eyes, photosensitiv-
ity, corneal ulceration, loss of vision (uncommon) are features of Graves associated 
orbitopathy (GAO) [13].
2.7 Skin and hair
Excessive sweating. Palmar erythema may resemble “liver palms,” and tel-
angiectasia may be present. Hair loss may increase. The nails are often soft and 
friable. A characteristic but uncommon finding is Plummer’s nails, or onycholy-
sis, typically involving the fourth and fifth fingers [11].
2.8 Respiratory system
Dyspnoea is common in severe thyrotoxicosis, mainly from weakness of the 
respiratory muscles.
2.9 Alimentary system
An increase in appetite is common but is inadequate to meet the increased 
caloric requirements. The frequency of bowel movements is increased and hepatic 
dysfunction occurs [14]. Hepatomegaly and jaundice can develop with severe, 
prolonged disease, and liver failure was a cause of death before the development of 
successful treatment for patients with Graves’ disease.
2.10 Haematopoietic system
The increase in erythropoiesis results from both a direct effect of thyroid 
hormones on the erythroid marrow and increased production of erythropoietin. 
Association of pernicious anaemia can be there in 3% of Graves of which 3% 
have auto-antibodies to intrinsic factor; accelerated clearance of the vitamin 
K-dependent clotting factors. Therefore, the dosage of warfarin needs to be reduced 
in thyotoxicosis [15].
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2.11 Reproductive function
Menstrual irregularity is common. Fertility may be reduced, and if conception 
takes place, there is an increased risk of miscarriage [16, 17]. The increased rate 
of conversion of androgens to estrogenic by-products may be the mechanism for 
gynecomastia and erectile dysfunction.
3. Graves’ disease
Popularly known as Robert Graves’ disease in English speaking world and as Von 
Basedow’s disease in Europe, although disease was first described by Parry in 1825 [11].
3.1 Presentation
Graves’ disease characteristics include goitre and thyrotoxicosis; common asso-
ciated features include orbitopathy (GAO) and dermopathy. The thyroid histology 
suggests autoimmune thyroiditis with the presence of lymphocytic infiltrate.
4. Pathogenesis
4.1 The major antigen of Graves’ disease: the thyrotropin receptor
The TSHR is a G protein coupled receptor. The TSHR is the primary auto antigen 
of Graves’ disease, experimentally proven with mice antigen antibody studies [18].
Figure 2. 
Patient of Graves disease showing diffuse goitre and eye signs.
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5. Diagnosis
It is always better to test TSH and T4 rather than testing TSH alone, measuring 
both T4 & TSH increases diagnostic accuracy. In case of overt hyperthyroidism T3 
and T4 are high and TSH is low and in subclinical disease T4 is usually normal TSH 
is usually suppressed, and T3 is normal or increased.
TSH-Receptor-Ab (TRAb) is a specific biomarker for Grave’s Disease. 
Immunoassays used nowadays do competitive assays which measure Thyroid 
Receptor binding inhibitory immunoglobulins (TBII) [19]. Bioassays can differenti-
ate between blocking and stimulating TRAB but its time consuming and a costly 
affair.
5.1 Imaging
Most clinicians would request thyroid ultrasound (US) and often isotope 
scanning is seldom available in India. Imaging tests are investigator dependant and 
hence experience and qualification of a person doing the test does matter, also mat-
ter is instruments used, hence a high-frequency linear probe should be used. GD 
is often, but not invariably, characterised by diffuse thyroid enlargement and by 
hypoechogenicity, both of which are assessed by ultra-sonogram and conventional 
grey scale analysis [20].
A colour-flow or power Doppler examination is characterised by vascular 
patterns and can quantify vascularity of thyroid [21]. Thyroid vascularity is signifi-
cantly increased in severe Grave’s disease and it typically shows a pulsatile pattern 
in thyroid gland which is called as “thyroid inferno” that is multiple small areas of 
increased intrathyroidal flow seen throughout the gland [22]. To measure accurately 
thyroid artery flow velocity and peak systolic velocity (PSV), it requires adjust-
ments of pulse repetition frequency of wall filters and control of the insonation 
angle between 0 and 60°. The PSV is capable of differentiation between GD related 
thyrotoxicosis or amiodarone-induced thyrotoxicosis type 2, where the blood flow 
is reduced [23]. A typical US finding along with TRAB results can make diagnosis 
almost certain but thyroid scintigraphy is needed prior to Radioactive iodine abla-
tion so that multinodular goitre can be differentiated [20].
6. Medical treatment
There are three ways by which GD is treated. One is by oral treatment with anti-
thyroid drugs which reduces synthesis of thyroid hormones second is Radioactive 
iodine ablation where radioactive iodine is used to burn thyroid follicles and third 
one being thyroid surgery where thyroid gland is removed so that thyroid synthesis-
ing machinery is taken outside the body [20, 24]. ATD represent the most com-
monly used therapy in Europe, Asia, and in the meantime in the USA [25, 26]. The 
main ATD are thionamides, such as propylthiouracil (PTU), carbimazole (CBZ), 
and the active metabolite of the CBZ as, methimazole (MMI). CBZ is not an active 
substance; it has to be decarboxylated to MMI in the liver. Thionamides inhibit the 
coupling of iodothyronines and hence reduce the biosynthesis of TH [27]. These 
drugs mainly inhibit function of thyroperoxidase, reducing oxidation and the 
organification of iodide. ATD are indicated as a first-line treatment of GD, particu-
larly in younger subjects, and for short-term treatment of GD before definitive RAI 
therapy or thyroidectomy [20]. ATD also helps to reduce TRAb levels and rates of 
remission of GD. PTU at very high doses also inhibits deiodination of T4 to T3 [28]. 
However, this effect is of use in case of thyrotoxicosis crisis but for long term use 
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this effect is not of much use. The starting dose of MMI is usually 10–30 mg daily 
in divided doses depending on the severity of hyperthyroidism (CBZ 15–60 mg/
day). PTU is given 100 mg every 8 h. titration regimen is used through the Corse 
of disease, means as disease goes in remission, dose is gradually reduced based on 
severity of the illness. Thyroid function tests are reviewed 3–4 weekly intervals 
after initial treatment, and the dose is titrated based on T4 and T3 levels. TSH values 
remain suppressed for long time hence more reliable is T3 & T4 reports but measur-
ing T4 does add value to report as sometimes overtreatment increases TSH values 
in short span. The usual daily maintenance doses of ATD in the titration regimen 
are 2.5–10 mg of MMI and 50–100 mg of PTU. Some have also advocated block and 
replacement regimen to avoid severe hypothyroidism during treatment where MMZ 
in dose of 30–50 mg daily along with thyroxin replacement is used throughout the 
Corse but side effects of ATD are more with this kind of regimen [28].
6.1 Adverse events
Common side effects of ATD are allergic reactions which include rash, urti-
caria, and arthralgia (1–5%). Minor cutaneous reactions are managed with anti-
histaminics without stopping the ATD. Substituting an ATD may also be helpful 
[28]. In the case of a serious allergic reaction like hepatitis, a lupus-like syndrome, 
and agranulocytosis (neutrophil count <500/mL), which occurs in 0.1–1.0% of 
cases, it’s better to avoid ATD in patients as risk of severity of allergic reaction may 
increase and it’s better to use alternative ways of treatment [29]. Agranulocytosis 
may occur abruptly within 3 months after the initiation of ATD therapy [30]. The 
risk of ATD-induced agranulocytosis and pancytopenia at 100 and 150 days after 
the initiation of ATD was 0.28 and 0.29%, respectively [31].
6.2 Beta adrenergic drugs (β blockers)
These drugs are used as second line treatment of adjunctive treatment. These 
reduce catecholamine response at receptor level hence this is a symptomatic 
treatment and not a definitive treatment. Tremulousness, palpitations, excessive 
sweating, eyelid retraction, and heart rate decrease; by reducing sympathetic 
hyperactivity which is induces by excess TH in blood. Propranolol (but not other 
β-adrenergic agents) may also weakly block the conversion of T4 to T3 via a mecha-
nism independent of its effect on catecholamine signalling. Propranolol is the most 
widely used agent because it is relatively free from adverse effects and has a short 
half-life. It can be given orally in a dose of 20–60 mg every 6 or 8 h and avoided in 
patients with known history of bronchial asthma or COPD with respiratory prob-
lems. Hypotension with Propranolol is unusual [32].
6.3 Radioablation
Introduced in the mid-1940s, a relatively inexpensive therapy for treatment of 
hyperthyroidism, 131I has become the most widely used therapy, although inter-
national questionnaire studies show that geographic differences do exist. The iso-
tope being used is 131I. It is given orally (in a capsule or in water) and is absorbed 
rapidly and completely, after which it is concentrated, oxidised, and organified 
by follicular thyroid cells. The ionising effect of β-particles, with a path length of 
1–2 mm, destroys the thyroid cells by an early inflammatory response, necrosis of 
follicular cells, and vascular occlusion. Further chronic inflammation and fibrosis 
result in a decrease in thyroid size and an impaired thyroid function. So most of 
the patients developed Hypothyroidism following 131I therapy [33].
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6.4 Dose calculation
Smallest possible dose is preferred so that to make patients euthyroid and avoid 
permanent hypothyroidism in patients. Dose is calculated by following algorithm:
Dose (mCi) = (80 - 200 micro Ci 131I/g thyroid × estimated thyroid gland 
weight (g) ÷ 24 h radioiodine uptake).
With use of above dose calculation algorithm, usual dose patients receive is 
5–15 mCi and many become euthyroid followed by hypothyroidism. Dose calcula-
tion is time consuming and costly hence fixed dose activity is commonly used 
in many centres which simplifies and reduces cost of 131I therapy and the lack 
of a significant difference in outcome between patients randomised to fixed and 
calculated 131I doses favour the use of fixed doses. Typically a patient with Graves’ 
disease requires 5–15 mCi, 10–29 mCi in patients with toxic nodule and toxic MNG 
[33]. Not all patients respond to 131I and these patients may require multiple doses 
at 6–12 monthly intervals. Patients who can be predicted to have poor response are: 
(1) age (>40 years); (2) Gender (female); (3) severe hyperthyroidism; (4) medium 
or large goitres (>40 g, visible); and (5) ATD pre-treatment (especially with 
propylthiouracil) [34].
6.5 Surgery
Thyroid surgery is oldest available treatment for hyperthyroidism and it’s a 
definitive treatment for the illness. Being an invasive treatment and also associated 
complications, its least preferred now a days, but indications for the treatment 
include: (1) patients preference; (2) large size goitres which are causing compressive 
symptoms or for cosmetic reasons; (3) Graves’ disease super imposed on endemic 
goitre with multiple cold nodules; (4) suspicion of malignancy; and (5) associated 
with ophthalmopathy.
6.6 Pre-operative preparation
It is mandatory to achieve normal metabolic state before patients undergo 
thyroid surgery or else patients may land u into thyroid storm. Normal metabolic 
state is generally achieved by using ATD in appropriate dose and duration. Beta 
blockers are also used in management to achieve eumetabolism before surgery. 
Once eumetabolism is achieved SSKI is added, 2–3 drops twice daily, for 7–10 days. 
Lugol’s iodine can also be used depending on its availability.
6.7 Treatment of sub-acute thyroiditis
Treatment is usually supportive and symptomatic. Pain is relieved with NSAID’s. 
If pain persists despite maximal NSAID’s, prednisolone in a dose of 40 mg per day 
for 7–10 days is followed [35].
7. Special situation
7.1 Hyperthyroidism in pregnancy
Hyperthyroidism is not uncommon during pregnancy with prevalence being 
0.1–0.4% of which 80% of the cases are of Grave’s disease. The activity level of 
Graves’ disease fluctuate during gestation, with exacerbation during the first 
trimester and improvement by late gestation related to autoimmune process of 
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the disease affected by gestation. Hyperthyroidism of Graves’ disease may also be 
aggravated by high levels of HCG in the first trimester. Because nonspecific symp-
toms of hyperthyroidism may be mimicked by normal pregnancy, the presence 
of a goitre, especially with a bruit or thrill, which may point to a diagnosis of true 
Graves’ disease. One has to be cautious before labelling diagnosis of Grave’s disease 
and should first rule out gestational thyrotoxicosis [36–38].
Patients suspected of having hyperthyroidism require measurement of serum 
TSH, T4, T3 levels, and TRAb. And it’s always necessary to interpret thyroid func-
tion tests in relation to the HCG-mediated decrease in serum TSH levels and the 
increase in T4 binding globulin concentrations that occur during normal pregnancy 
[39–41].
In a normal pregnancy TSH is typically suppressed specially during late first tri-
mester and last trimester, a lady with Graves’ disease, one must anticipate transpla-
cental transfer of TRAB and fetal hyperthyroidism hence adequate treatment of a 
pregnant woman is necessary to avoid fetal hyperthyroidism. Fetal hyperthyroidism 
and inadequate treatment is associated with increased risk of medically indicated 
preterm delivery, intrauterine growth restriction and low birth weight, pre-
eclampsia, congestive heart failure, and fetal death [42]. In addition, overtreatment 
of the mother with thionamides can result in iatrogenic fetal hypothyroidism [43], 
but under treatment of maternal hyperthyroidism may lead to central congenital 
hypothyroidism [44, 45].
Fetal hyperthyroidism is known to be associated with intrauterine growth 
restriction, fetal tachycardia, fetal goitre, advanced bone age, fetal hydrops, 
preterm delivery, and fetal death [46]. The diagnosis is suggested by any of these 
signs or abnormalities. Maternal TRAb levels able to induce fetal hyperthyroidism 
are usually over three times the upper normal limit. PTU and MMI or its derivative 
carbimazole are the mainstays of treatment. Recently, the Adverse Event Reporting 
System of the FDA has focused attention on the relation between hepatotoxicity 
and PTU [47]. This finding has led to a recommendation that PTU use in pregnancy 
should be limited to the first trimester, and then treatment must be switched to 
MMI. Use of MMI during the first trimester has been associated with a possible 
embryopathy.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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